Eagle Global Advisors’s Traws Pharma TRAW Stock Holding History

Eagle Global Advisors’s Portfolio TRAW Stock Details TRAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-3	Closed	-$44K	–	410
2016 Q3	$44K	Buy	+3	New	+$61.3K	﹤0.01%	353

Other funds holding TRAW

TCP

Tyndall Capital Partners New York $452K AUM 26.52% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WMSA

Weiss Multi-Strategy Advisers New York $4.16B AUM 30.77% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

AIM

Acrospire Investment Management Chicago, Illinois $33K AUM 23.36% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Eagle Global Advisors's TRAW Position: Q4 2016 in Review

Eagle Global Advisors sold out of Traws Pharma (TRAW) in Q4 2016, closing a stake of 3 shares — an estimated $44K sold.

Eagle Global Advisors first reported a position in TRAW in Q3 2016 and held it in 1 quarter. The position peaked at $44K in Q3 2016. 10 funds tracked by Wall St. Rank hold TRAW as of Q4 2016.

Eagle Global Advisors reported no remaining Traws Pharma position as of Q4 2016 after selling out during the quarter.
Eagle Global Advisors sold 3 Traws Pharma shares in Q4 2016, an estimated $44K.
Eagle Global Advisors first reported a position in Traws Pharma in Q3 2016 and held it in 1 quarter.
Eagle Global Advisors's Traws Pharma position peaked at $44K in Q3 2016.
10 funds tracked by Wall St. Rank held Traws Pharma as of Q4 2016.

Based on Eagle Global Advisors's 13F filing for Q4 2016, filed 14 Feb 2017.